Technology Developed by Liotta and Petricoin Used to Test Chloroquine to Treat Breast Cancer

The research will use reverse-phase protein microarray technology developed by Liotta and Petricoin to create a proteomic profile of tissue samples from trial participants in order to show which protein pathways or drug targets are activated, and then determine whether chloroquine has any effect as a treatment.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.